Zobrazeno 1 - 10
of 14
pro vyhledávání: ''
Autor:
Hewei Li, Karijn P M Suijkerbuijk, Christopher D. Lao, David A. Reardon, F. Stephen Hodi, Alexandre Avila, Bartosz Chmielowski, William H. Sharfman, Sergio J Azevedo, James Larkin, Daniel Reshef, Jeffrey S. Weber
Background Despite unprecedented efficacy across multiple tumor types, immune checkpoint inhibitor therapy is associated with a unique and wide spectrum of immune-related adverse events (irAEs), including neurologic events ranging from mild headache
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be2f7112be3d6e470186be49f7118afa
https://europepmc.org/articles/PMC5469590/
https://europepmc.org/articles/PMC5469590/
Autor:
Gary Meyer, Deborah Schrag, Jeffrey A. Meyerhardt, Brian M. Wolpin, Charles S. Fuchs, Thomas A. Abrams
Purpose Few population studies have examined patterns of systemic therapy administration in metastatic pancreatic cancer (MPC) or the predictors associated with specific treatment choices. Patients and methods We assessed 4,011 consecutive MPC patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb0230f1955a923a76543ca244077281
https://europepmc.org/articles/PMC5553956/
https://europepmc.org/articles/PMC5553956/
Autor:
Chikamasa Yoshida, Daigo Niiya, Yoshihiro Hatta, Koichi Kitazume, Takaaki Miyake, Masatoshi Kanno, Jun Murakami, Kazuhiko Yamamoto, Masatoshi Uno, Hideki Tsujimura, Yasufumi Masaki, Rika Sakai, Atsuko Hojo, Jun Ozaki, Yoshinobu Maeda, Kazutoshi Aoyama, Jun Takizawa, Katsuhiro Miura, Tomofumi Yano, Jun Konishi, Masanori Makita, Kazutaka Sunami, Yasushi Hiramatsu
Background Decision-making models for elderly patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) are in great demand. Patients and Methods The Society of Lym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0ea18beefff01a59a3682d6f3c03cd6
https://europepmc.org/articles/PMC5423505/
https://europepmc.org/articles/PMC5423505/
Autor:
Chia Jui Yen, Manish A. Shah, David S. Shames, Yoon-Koo Kang, Lilian Bu, Jae Yong Cho, Niall C. Tebbutt, Iain Beehuat Tan, Alice Kang
Background The phase II YO28252 study (NCT01590719) examined first-line onartuzumab plus mFOLFOX6 in patients with metastatic, human epidermal growth factor receptor 2-negative adenocarcinoma of the stomach or gastroesophageal junction. MET immunohis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4cb6418ea1d5c9605b58420b560c3f7
https://europepmc.org/articles/PMC5016069/
https://europepmc.org/articles/PMC5016069/
Autor:
Michael Mian, Alessandra Marabese, Normann Steiner, Wolfgang Willenbacher, Simone Ferrero, Paola Ghione, Patrizia Mondello, Vincenzo Pitini, Salvatore Cuzzocrea
Publikováno v:
Europe PubMed Central
Despite the advent of new treatment strategies, many patients with diffuse large B-cell lymphoma (DLBCL) relapse or die of the disease. Prospective clinical trials have demonstrated that lenalidomide is an effective and safe treatment option, especia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33ee1709e13e42477e44024f95b563c1
https://europepmc.org/articles/PMC5016065/
https://europepmc.org/articles/PMC5016065/
Autor:
Yen Han Tseng, Reury Perng Perng, Yu Chin Lee, Yi Hsuan Lin, Jacqueline Whang-Peng, Yuh Min Chen, Yen Chiang Tseng
Background. Lung cancer is frequently a disease of elderly patients. However, these patients are often treated less actively owing to a higher comorbidity rate and poor performance status. The efficacy of different treatments in elderly patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::affb45cdb841f7826ef59ddf92ee9292
https://europepmc.org/articles/PMC4492228/
https://europepmc.org/articles/PMC4492228/
Autor:
Steven J. Cohen, Jerome C. Landry, Udit Verma, Halla Sayed Nimeiri, Roshan S. Prabhu, Elin R. Sigurdson, Al B. Benson, Charles A. Staley, Richard M. Whittington, Yang Feng
Lessons Learned The 5-year oncologic outcomes from the trial regimen were excellent. However, the neoadjuvant and surgical toxicity of this regimen was significant and was the primary reason for the low compliance with adjuvant systemic therapy. Due
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff9752c038654084760c26aef4c410d
https://europepmc.org/articles/PMC4571787/
https://europepmc.org/articles/PMC4571787/
Autor:
Hawk Kim, Dong Wan Kim, Hong Suk Song, Sung Hwa Bae, Yoon Kyung Jeon, Byung Soo Kim, Dae Seog Heo, Tae Min Kim, Joo-Seop Chung, Young Jin Yuh, Myung Soo Hyun, Chul Woo Kim, Sung Hyun Yang, Yoon-Koo Kang, Hyo Jung Kim, Jong Seok Lee
Background. Combination chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) was active as first-line and second-line treatment for extranodal natural killer/T-cell lymphoma (NTCL). Methods. Forty-four patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f23327949610d273ea069b1337810354
https://europepmc.org/articles/PMC4221378/
https://europepmc.org/articles/PMC4221378/
Autor:
Onne Reerink, Richard van Hillegersberg, Martijn P. Lolkema, Harm K. Wijrdeman, Pieter C. van der Sluis, Marriete Agterof, Frank P. Vleggaar, Inge Ubink, Marguerite E.I. Schipper, Esther N.M. Overkleeft, Inne Borel-Rinkes, Emile E. Voest, Peter D. Siersema
Background. Local and systemic recurrence are important sources of treatment failure following surgical resection of esophageal adenocarcinoma. We hypothesized that adding preoperative cetuximab and radiotherapy (cetux-RT) to perioperative chemothera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd20d9df8c68016d2e55f88683e437b8
https://europepmc.org/articles/PMC3903062/
https://europepmc.org/articles/PMC3903062/
Autor:
David W. Rattner, Harvey J. Mamon, Jeffrey A. Meyerhardt, Peter C. Enzinger, Michael S. Lee, Panagiotis Fidias, Michael T. Jaklitsch, Michael Lanuti, David P. Ryan, Charles S. Fuchs, Noah C. Choi, Raphael Bueno, Theodore S. Hong, Eunice L. Kwak, Dean M. Donahue
Purpose. To determine the efficacy and toxicity of weekly neoadjuvant cetuximab combined with irinotecan, cisplatin, and radiation therapy in patients with locally advanced esophageal or gastroesophageal junction cancer. Methods and Materials. Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cb7c5a3244b8258b75775312fb2f336
https://europepmc.org/articles/PMC3607524/
https://europepmc.org/articles/PMC3607524/